Sympathetic signatures of cardiovascular disease: A blueprint for development of targeted sympathetic ablation therapies

Hypertension

Volumn 59, Issue 3, 2012, Pages 545-547

  Osborn, John W ^a   Kuroki, Marcos T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; NORADRENALIN; PRAZOSIN; RESERPINE;

ABLATION THERAPY; CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; SYMPATHETIC ABLATION; SYMPATHETIC TONE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; HEART; HEART FAILURE; KIDNEY; LOSARTAN; SYMPATHETIC NERVOUS SYSTEM;

EID: 84857636049     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.182899     Document Type: Note

References (10)

1. Esler M. Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2010;108:227-337.
2. Chobanian AV. The hypertension paradox: more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878-897.
3. McAllen RM, May CN. Differential drives from rostral ventrolateral medullary neurons to three identified sympathetic outflows. Am J Physiol. 1994;267:R935-R944.
4. Morrison SF. Differential control of sympathetic outflow. Am J Physiol. 2001;281:R683-R696.
5. Ramchandra R, Hood SG, Watson AMD, Allen AM, May CN. Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure. Hypertension. 2012;59: 634-641.
6. Yoshimoto M, Wehrwein EA, Novotny M, Swain GM, Kreulen DL, Osborn JW. Effect of stellate ganglionectomy on basal cardiovascular function and responses to -1 adrenoceptor blockade in the rat. Am J Physiol Heart Circ Physiol. 2008;295:H2447-H2454.
7. Osborn JW, Fink GD, Kuroki MT. Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchinc circulation. Curr Hypertens Rep. 2011;13:221-228.
8. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
9. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler M. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.
10. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension. Circulation. 2011;123: 1940-1946.